Cargando…

Differences in reimbursement listing of anticancer therapies in China: an observational study

OBJECTIVE: Access to highly priced anticancer medications usually requires insurance coverage. A first step towards coverage of such medications is their inclusion in reimbursement lists. We assessed listing for reimbursement in China between 2009 and 2018 of anticancer medications on the WHO’s Esse...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guan, Xiaodong, Zhang, Yichen, Wushouer, Haishaerjiang, Shi, Luwen, Ross-Degnan, Dennis, Wagner, Anita Katharina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Health Policy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6955534/ https://www.ncbi.nlm.nih.gov/pubmed/31911513 http://dx.doi.org/10.1136/bmjopen-2019-031203

Ejemplares similares

Influence of government price regulation and deregulation on the price of antineoplastic medications in China: a controlled interrupted time series study
por: Guan, Xiaodong, et al.
Publicado: (2019)

The impacts of government reimbursement negotiation on targeted anticancer medication price, volume and spending in China
por: Zhang, Yichen, et al.
Publicado: (2021)

Outpatient prescribing pattern for acute bronchitis in primary healthcare settings in China
por: Fu, Mengyuan, et al.
Publicado: (2021)

The Impact of Sanming Healthcare Reform on Antibiotic Appropriate Use in County Hospitals in China
por: Hu, Lin, et al.
Publicado: (2022)

Impacts of adjustment of National Reimbursement Drug List on orphan drugs volume and spending in China: an interrupted time series analysis
por: Yi, Hongbin, et al.
Publicado: (2023)

Influence of Government Price Regulation on the Price, Volume and Spending of Antibiotics in China: A Controlled Interrupted Time Series Study
por: Wushouer, Haishaerjiang, et al.
Publicado: (2020)

Trends of Negotiated Targeted Anticancer Medicines Use in China: An Interrupted Time Series Analysis
por: Huang, Cong, et al.
Publicado: (2021)

The impact of government reimbursement negotiation on targeted anticancer medicines use and cost in China: A cohort study based on national health insurance data
por: Yang, Yu, et al.
Publicado: (2023)

Health technology assessment-informed pricing negotiation in China: higher negotiated price for more effective targeted anticancer medicines?
por: Huang, Cong, et al.
Publicado: (2022)

Medical insurance and healthcare utilization among the middle-aged and elderly in China: evidence from the China health and retirement longitudinal study 2011, 2013 and 2015
por: Zhou, Yue, et al.
Publicado: (2020)

Health Care Utilization and Costs of Patients With Prostate Cancer in China Based on National Health Insurance Database From 2015 to 2017
por: Bai, Lin, et al.
Publicado: (2020)

Interrupted time-series analysis of the impact of generic market entry of antineoplastic products in China
por: Guan, Xiaodong, et al.
Publicado: (2018)

Secular trend analysis of antibiotic utilisation in China’s hospitals 2011–2018, a retrospective analysis of procurement data
por: Wushouer, Haishaerjiang, et al.
Publicado: (2020)

Outpatient Antibiotic Prescribing Patterns and Appropriateness for Children in Primary Healthcare Settings in Beijing City, China, 2017–2019
por: Wushouer, Haishaerjiang, et al.
Publicado: (2021)

Expanding access to high-cost medicines through the E2 access program in Thailand: effects on utilisation, health outcomes and cost using an interrupted time-series analysis
por: Sruamsiri, Rosarin, et al.
Publicado: (2016)

The impact of physicians’ knowledge on outpatient antibiotic use: Evidence from China's county hospitals
por: Wushouer, Haishaerjiang, et al.
Publicado: (2020)

Acid Suppression Use Among Infants in One Tertiary Children's Hospital in China, 2015–2018: A Retrospective Observational Study
por: Zhou, Yue, et al.
Publicado: (2021)

Protocol of a tailored educational intervention for general practitioners on potentially inappropriate medications among older patients at community healthcare institutions in Beijing, China: a cluster-randomised controlled trial
por: Fu, Mengyuan, et al.
Publicado: (2021)

Impact of the National Reimbursement Drug List Negotiation Policy on Accessibility of Anticancer Drugs in China: An Interrupted Time Series Study
por: Zhu, Hong, et al.
Publicado: (2022)

Economic Implications of Potential Changes to Regulatory and Reimbursement Policies for Medical Devices
por: Reed, Shelby D., et al.
Publicado: (2007)

Clinical Outcome and Medical Cost of Originator and Generic Antihypertensive Drugs: A Population-Based Study in Yinzhou, China
por: Huang, Tao, et al.
Publicado: (2022)

Effect of reimbursement restriction policy on the use of benzodiazepines in the Netherlands: an interrupted time series analysis
por: Stoker, Lennart Jan, et al.
Publicado: (2019)

Anticancer medicines in China: Trends in daily therapy cost and relative procurement volume and spending
por: Huang, Tao, et al.
Publicado: (2021)

Antibiotic use and irrational antibiotic prescriptions in 66 primary healthcare institutions in Beijing City, China, 2015–2018
por: Taxifulati, Yumiti, et al.
Publicado: (2021)

Inpatient antibacterial use trends and patterns, China, 2013–2021
por: Wushouer, Haishaerjiang, et al.
Publicado: (2023)

Study protocol for the evaluation of pharmacist-participated medication reconciliation at county hospitals in China: a multicentre, open-label, assessor-blinded, non-randomised, controlled study
por: Yu, Aichen, et al.
Publicado: (2022)

Trends in high deductible health plan enrolment and spending among commercially insured members with and without chronic conditions: a Natural Experiment for Translation in Diabetes (NEXT-D2) Study
por: Garabedian, Laura F, et al.
Publicado: (2021)

Emergency Physician Reimbursement: Getting Shortchanged or Shrewdly Negotiating?
por: Venkatesh, Arjun K., et al.
Publicado: (2020)

Effects of removing reimbursement restrictions on targeted therapy accessibility for non-small cell lung cancer treatment in Taiwan: an interrupted time series study
por: Hsu, Jason C, et al.
Publicado: (2019)

Trends of Fixed-Dose Combination Antibiotic Consumption in Hospitals in China: Analysis of Data from the Center for Antibacterial Surveillance, 2013–2019
por: Wushouer, Haishaerjiang, et al.
Publicado: (2022)

Close cooperation with Health Technology Assessment expertise is crucial for implementation and ultimately reimbursement of innovations in oncology
por: van Harten, WH, et al.
Publicado: (2016)

Evaluation of prescription review and feedback policy on rational antibiotic use in primary healthcare settings in Beijing, China: a qualitative study using the Theoretical Domains Framework and the behaviour change wheel
por: Wushouer, Haishaerjiang, et al.
Publicado: (2023)

Overall survival benefits of cancer drugs in the WHO Model List of Essential Medicines, 2015–2021
por: Zhou, Yue, et al.
Publicado: (2023)

Prices and Clinical Benefit of National Price-Negotiated Anticancer Medicines in China
por: Zhang, Yichen, et al.
Publicado: (2022)

Drug approval status and recommendations for listing on public formularies: a Canadian cohort analysis
por: Lexchin, Joel
Publicado: (2017)

Drug pricing and reimbursement decision making systems in Mongolia
por: Dorj, Gereltuya, et al.
Publicado: (2017)

Sales of anti-cancer medicines; China, Indonesia, Kazakhstan, Malaysia, Philippines and Thailand
por: Ferrario, Alessandra, et al.
Publicado: (2020)

Trends and patterns of antibiotic consumption in China’s tertiary hospitals: Based on a 5 year surveillance with sales records, 2011-2015
por: Wushouer, Haishaerjiang, et al.
Publicado: (2017)

Development trend of primary healthcare after health reform in China: a longitudinal observational study
por: Feng, Jie, et al.
Publicado: (2022)

Sponsorship bias in published pharmacoeconomic evaluations of national reimbursement negotiation drugs in China: a systematic review
por: He, Zixuan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_a9v577g3ip0gnr2q804safnbhp